Abstract:Familial hypercholesterolaemia (FH), a common monogenic disorder, is a preventable cause of premature coronary artery disease and death. Up to 35 million people worldwide have FH, but most remain undetected and undertreated. Several clinical guidelines have addressed the gaps in care of FH, but little focus has been given to implementation science and practice. The International Atherosclerosis Society (IAS) has developed an evidence-informed guidance for the detection and management of patients with FH, supplemented with implementation strategies to optimize contextual models of care. The guidance is partitioned into detection, management and implementation sections. Detection deals with screening, diagnosis, genetic testing and counselling. Management includes risk stratification, treatment of adults and children with heterozygous and homozygous FH, management of FH during pregnancy, and use of lipoprotein apheresis. Specific and general implementation strategies, guided by processes specified by the Expert Recommendations for Implementing Change taxonomy, are provided. Core generic implementation strategies are given for improving care. Nation-specific cholesterol awareness campaigns should be utilized to promote better detection of FH. Integrated models of care should be underpinned by health policy and adapted to meet local, regional and national needs. Clinical centres of excellence are important for taking referrals from the community. General practitioners should work seamlessly with multidisciplinary teams. All health-care providers must receive training in essential skills for caring for patients and families with FH. Management should be supported by shared decision-making and service improvement driven by patient-reported outcomes. Improvements in services require sharing of existing resources that can support care. Advocacy should be utilized to ensure sustainable funding. Digital health technologies and clinical quality registries have special value. Finally, academic-service partnerships need to be developed to identify gaps in care and set priorities for research. This new IAS guidance on FH complements the recent World Heart Federation Cholesterol Roadmap.

Advances in familial hypercholesterolemia

Familial Hypercholesterolemia: Current Limitations and Future Breakthroughs

[Advances in Diagnosis and Treatment of Familial Hypercholesterolemia].

Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation

Unveiling Familial Hypercholesterolemia—Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy

Research Progress in the Clinical Treatment of Familial Hypercholesterolemia

Recent progress in gene therapy for familial hypercholesterolemia treatment

Novel Approaches for the Treatment of Familial Hypercholesterolemia: Current Status and Future Challenges.

International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia

Consensus document on diagnosis and management of Familial Hypercholesterolemia from the Italian Society for the study of Atherosclerosis (SISA)

Recent Advances in Gene Therapy for Familial Hypercholesterolemia: An Update Review

International Atherosclerosis Society Roadmap for Familial Hypercholesterolaemia

Applications of machine learning in familial hypercholesterolemia

Genetic Counseling and Genetic Testing for Familial Hypercholesterolemia

Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors

Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action

Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia

Familial Hypercholesterolemia in Asia Pacific: A Review of Epidemiology, Diagnosis, and Management in the Region

Review of the scientific evolution of gene therapy for the treatment of homozygous familial hypercholesterolaemia: past, present and future perspectives

Potentials of artificial intelligence in familial hypercholesterolemia: Advances in screening, diagnosis, and risk stratification for early intervention and treatment

Advances with lipid-lowering drugs for pediatric patients with familial hypercholesterolemia